AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development model

AI is quickly becoming a central force in drug development as tech capital pours into biopharma, reshaping how new medicines are discovered.

Tyrone Lam, chief business officer at GATC Health, says the influx of tech investors creates pressure on drugmakers to lower failure rates by embracing a "fail-fast" approach.

The model calls for AI not only to speed molecule design but to assess risk early, moving de‑risking activities to the front of the development pipeline.

Lam believes the true paradigm shift will be using predictive AI tools throughout the value chain, allowing companies to identify potential failures before costly clinical stages.